Express uses B cells to cross the blood-brain barrier to deliver protein drugs, and US$900 million helps develop new cell therapies

▎ WuXi AppTec content team editor October 13, 2021, Immusoft announced that it has signed a research cooperation and licensing option agreement with Takeda, which will use Immusoft’s immune system programming ISP technology platform to discover, develop and commercialize Transformative cell therapy for the treatment of rare genetic metabolic disorders
.

This cooperation will focus on the delivery of protein therapeutic drugs across the blood-brain barrier, which is expected to achieve the treatment of diseases with high unmet needs
.

The ISP (Immune system Programming) platform can use the patient's own cells to achieve continuous delivery of protein therapy
.

The ISP collects the patient's immune B cells
.

After being stimulated by the immune system, B cells can be transformed into plasma cells.
It is like a "biological factory" that can produce and secrete thousands of antibodies every second
.

ISP can reprogram B cells and differentiate them into plasma cells, and then return them to the patient's body, so as to achieve a large amount of long-lasting production of therapeutic proteins
.

▲Immusoft's ISP platform mechanism (picture source: Immusoft's official website) According to the terms of the agreement, Immusoft will receive an undisclosed advance payment and research funding support, and is eligible for milestone payments, with a total amount of more than 900 million US dollars
.

Takeda will be responsible for the further preclinical, clinical development and commercialization of the product
.

Mr.
Sean Ainsworth, CEO of Immusoft, said: "We are very pleased to have reached this cooperation with Takeda
.

This partnership allows Immusoft to further develop the ISP technology platform to treat diseases with limited patient options
.

"Dr.
Madhu Natarajan, head of Takeda's Rare Disease Drug Discovery Department, said: "We will continue to build our internal capabilities and cooperate with innovative companies in the early detection process to advance our next-generation gene and cell therapies to treat rare genetics.
And blood diseases
.

We hope to validate Immusoft's ISP technology and realize the central nervous system delivery of innovative treatments for rare neurometabolic diseases
.

"Reference: [1] Immusoft And Takeda Collaborate To Discover And Develop Cell Therapies For Rare Neurometabolic Disorders.
Retrieved October 13, 2021, from https:// -collaborate-to-discover-and-develop-cell-therapies-for-rare-neurometabolic-disorders/Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is only for the purpose of information exchange, the views in the article It does not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views contained in the article
.

This article is not a treatment plan recommendation
.

If you need treatment plan guidance, please go to a regular hospital
.